425: Denali Capital Acquisition Corp. Faces Nasdaq Delisting Due to Non-Compliance with Listing Rules

Denali Capital Acquisition Corp. receives notification of delisting from Nasdaq due to failure to meet minimum Market Value of Listed Securities, Total Assets, and Public Float requirements.

Summary

• Denali Capital Acquisition Corp. received a delisting notice from Nasdaq on April 2, 2025, because it failed to comply with several listing rules.
• The company did not maintain a minimum Market Value of Listed Securities (MVLS) of $50.0 million.
• It also failed to maintain total assets and total revenue of at least $50.0 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years.
• Additionally, the company did not maintain a minimum of 1,100,000 publicly held shares.
• Unless the company appeals by April 9, 2025, trading of its securities will be suspended on April 11, 2025.
• Following delisting from Nasdaq, the company's securities are expected to commence trading on the OTC market.
• The company anticipates that the delisting will not immediately impact its proposed business combination with Semnur Pharmaceuticals, Inc.
• Denali Capital Acquisition Corp. plans to remain a reporting entity under the Securities Exchange Act of 1934 and continue filing reports with the SEC.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and failure to meet listing requirements, although the company is trying to maintain a positive outlook regarding the business combination.

Positives

• The company anticipates that the delisting will not immediately impact its proposed business combination with Semnur Pharmaceuticals, Inc.
• Denali Capital Acquisition Corp. plans to remain a reporting entity under the Securities Exchange Act of 1934 and continue filing reports with the SEC.

Negatives

• Denali Capital Acquisition Corp. received a delisting notice from Nasdaq due to non-compliance with listing rules.
• The company failed to meet the minimum Market Value of Listed Securities (MVLS) of $50.0 million.
• The company failed to maintain total assets and total revenue of at least $50.0 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years.
• The company failed to maintain a minimum of 1,100,000 publicly held shares.
• Trading of the company's securities will be suspended on April 11, 2025, if no appeal is made by April 9, 2025.

Risks

• The company faces the risk of delisting from The Nasdaq Global Market.
• There is no assurance that the company will achieve its expectations regarding trading on the OTC market.
• The proposed business combination with Semnur Pharmaceuticals, Inc. could be impacted despite the company's anticipation.

Future Outlook

The company expects to commence trading on the OTC market shortly after delisting and anticipates that the delisting will not immediately impact its proposed business combination with Semnur Pharmaceuticals, Inc. The company plans to remain a reporting entity under the Securities Exchange Act of 1934.

Management Comments

• The delisting from Nasdaq and the commencement of trading on the OTC market is not expected to immediately impact the Company's previously announced business combination with Semnur Pharmaceuticals, Inc.
• The Company anticipates that the parties will continue to work towards effectuating completion of that business combination.

Industry Context

The delisting of a SPAC like Denali Capital Acquisition Corp. highlights the challenges faced by companies in maintaining listing requirements, especially in a volatile market. Many SPACs formed in 2020 and 2021 are now struggling to find suitable targets or maintain their valuations, leading to potential delistings or liquidations.

Comparison to Industry Standards

• Many SPACs that went public in 2020 and 2021 are now facing similar challenges in maintaining listing requirements due to declining market valuations and difficulties in completing business combinations.
• Companies like Faraday Future and Lordstown Motors have also faced delisting warnings due to low stock prices and failure to meet Nasdaq's minimum requirements.
• The average SPAC has seen its share price decline significantly since its initial offering, reflecting broader market concerns about the SPAC structure and the quality of target companies.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the delisting.
• The company's reputation may be negatively impacted.
• The delisting could affect the company's ability to raise capital in the future.

Next Steps

• The company must decide whether to appeal the delisting determination by April 9, 2025.
• If no appeal is made, trading of the company's securities will be suspended on April 11, 2025.
• The company expects to begin trading on the OTC market shortly after delisting.
• The company will continue to work towards completing its proposed business combination with Semnur Pharmaceuticals, Inc.
• The company will continue to file periodic and current reports with the SEC.

Key Dates

Keywords

delisting, Nasdaq, compliance, MVLS, public float, Semnur Pharmaceuticals, business combination, OTC market, Denali Capital Acquisition Corp.